Twist Bioscience Corp (TWST): Entry into a Material Definitive Agreement
Twist Bioscience Corp (TWST) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 tm2622018d2_ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 TWIST BIOSCIENCE CORPORATION 3,125,000 Shares of Common Stock Underwriting Agreement August 4, 2026 Goldman Sachs & Co. LLC William Blair & Company, L.L.C. Leerink Partners LLC Guggenheim Securities, LLC As Representatives of
How this was made
The 30-second read
Why it matters
A priced follow-on equity offering introduces new share supply and can affect valuation multiples and near-term liquidity. The key tradable inputs are the priced purchase price ($91.20) and the total potential shares (3,125,000 plus up to 468,750 option shares).
Market read
This is a fresh, primary-source disclosure of a priced equity issuance, which can drive immediate positioning around dilution and deal absorption.
What to watch
Traders will want the final prospectus details: net proceeds, use of funds, any concurrent buyback/financing actions, and whether the option shares are likely to be exercised.
Background
The filing is an SEC Form 8-K reporting entry into a material definitive agreement, specifically an underwriting agreement for a common stock offering.
Ticker impact
Twist Bioscience entered an underwriting agreement to issue 3,125,000 shares, with an option for 468,750 more at $91.20 per share.
Likely near-term downside or volatility around offering execution, with direction depending on deal size vs demand and any concurrent guidance not shown here.
This is a primary capital-raise disclosure with hard terms (share count and purchase price), but the excerpt does not include net proceeds, use of funds, or offering size relative to float, limiting precision.
Market effects
Biotech tools and services names can see read-across from equity issuance risk, especially when offerings are priced at a specific per-share level.
Primarily US-listed small/mid-cap biotech sentiment; limited direct regional spillover beyond US biotech complex.
Low global relevance unless the proceeds fund major international expansion or partnerships, which are not specified in the provided excerpt.
Counterpoint
If the offering is well-supported and funds accretive growth (not shown here), the market may quickly re-rate the stock despite dilution.
Key entities
- issuerTwist Bioscience Corporation
Subject of the 8-K, entering an underwriting agreement for a common stock offering.
- underwriterGoldman Sachs & Co. LLC
Named as an underwriter and representative c/o in the underwriting agreement.
- underwriterWilliam Blair & Company, L.L.C.
Named as an underwriter and representative c/o in the underwriting agreement.
- underwriterLeerink Partners LLC
Named as an underwriter and representative c/o in the underwriting agreement.
- underwriterGuggenheim Securities, LLC
Named as an underwriter and representative c/o in the underwriting agreement.
